Lv6
1820 积分 2024-11-27 加入
Impurity Control Strategy of TMS-Triol in the Manufacture Development of Islatravir
14天前
已完结
Characterization of low-level D-amino acid isomeric impurities of Semaglutide using liquid chromatography-high resolution tandem mass spectrometry
1个月前
已完结
Determination of Purge Factors for Use in Oligonucleotide Control Strategies
1个月前
已完结
The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management
2个月前
已完结
Development of GSK's reagent guides – embedding sustainability into reagent selection
3个月前
已完结
Large-Scale Amidations in Process Chemistry: Practical Considerations for Reagent Selection and Reaction Execution
3个月前
已完结
Biopharmaceuticals: CMC Development “Points to Consider” from a Regulatory Perspective
3个月前
已完结
QbD Approach to Process Characterization and Quantitative Criticality Assessment of Process Parameters
3个月前
已完结
Application of a Statistical Approach to Process Development of Futibatinib by Employing Quality-by-Design Principles. Part 3: Development of Design Space for Control of Particle Size Distribution
3个月前
已完结
Application of a Statistical Approach to Process Development of Futibatinib by Employing Quality-by-Design Principles. Part 1: Identification of Critical Process Parameters for Impurities
3个月前
已完结
皖公网安备34019202002308
